Educational Programmes

The Educational Programmes on this page cover the following items:

Useful resources

GU CONNECT Update from…

Your clinical questions answered

Please submit your clinical topic for the next GU CONNECT newsletter here.

Treatment sequencing for mCRPC patients within the changing landscape of mHSPC: An engaging discussion during ESMO 2019

Dr. Cora Sternberg led an interesting Experts Knowledge Share on the topic of ‘Treatment sequencing for mCRPC patients within the changing landscape of mHSPC’ with Dr. Gert Attard and Dr. Alicia Morgans presenting two alternative treatment approaches.

Go to Programme

New therapies for metastatic hormone sensitive prostate cancer

As an experienced urologist and member of GU CONNECT, Prof. David Pfister provides his perspective on new therapies for mHSPC.

Go to Programme

Treating Oligometastatic Prostate Cancer

Assoc. Prof. Tanya B. Dorff looks into the use of imaging along with the treatment of oligometastatic prostate cancer

Go to Programme

Newly defined criteria for “platinum-ineligible” patients with metastatic urothelial cancer (mUC)

Asst. Prof. Shilpa Gupta discusses the newly defined criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer on behalf of the Platinum-Ineligibility in Bladder Cancer Working Group.

Go to Programme

An update on the treatment of patients with mCRPC with RA-223 plus AAP

Dr. Tia Higano provides her perspective on ERA 223: A phase 3 trial of Ra-223 in combination with AAP in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant mCRPC

Go to Programme

Advances in metastatic hormone-sensitive prostate cancer

Associate Professor Alicia Morgans provides her thoughts on the recent advances in metastatic hormone-sensitive prostate cancer

Go to Programme

How to use combination, sequential and immuno-oncology therapies in mCRPC?

Professor of Medicine Evan Yu and Associate Professor Tanya Dorff provide their thoughts and views on combination, sequential and immuno-oncology therapies in mCRPC (Metastatic Castration-Resistant Prostate Cancer)

Go to Programme

An update on recent cutting-edge trials: Treatments now available for newly diagnosed mHSPC patients

Dr. Neal Shore, Assoc. Prof. Neeraj Agarwal and Prof. Steven Joniau provide their thoughts and views on treatments for newly diagnosed mHSPC (Metastatic Hormone Sensitive Prostate Cancer) patients following recent cutting-edge trials.

Go to Programme

Relevant papers discussed